Analyst Reco. Abbott Laboratories

Equities

ABT

US0028241000

Real-time Estimate Cboe BZX Other stock markets 03:18:37 2024-05-28 pm EDT			5-day change	1st Jan Change
101.6 ^USD	-2.22%		-1.31%	-7.69%

May. 23	Medtronic beats quarterly profit estimates on medical devices strength	RE
May. 22	Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts Price Target on Abbott Laboratories to $119 From $128, Keeps Buy Rating	May. 22	MT
Abbott Laboratories Insider Sold Shares Worth $2,428,119, According to a Recent SEC Filing	May. 08	MT
Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126	Apr. 23	MT
Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating	Apr. 22	MT
UBS Raises Abbott Laboratories Price Target to $143 from $136, Buy Rating Kept	Apr. 19	MT
RBC Lowers Price Target on Abbott Laboratories to $125 From $128, Keeps Outperform Rating	Apr. 18	MT
Raymond James Adjusts Abbott Laboratories' Price Target to $124 From $127, Keeps Outperform Rating	Apr. 18	MT
Citigroup Raises Price Target on Abbott Laboratories to $128 From $126, Keeps Buy Rating	Apr. 03	MT
Barclays Raises Abbott Laboratories' Price Target to $141 From $133, Keeps Overweight Rating	Jan. 26	MT
Raymond James Adjusts Price Target on Abbott Laboratories to $127 From $124, Maintains Outperform Rating	Jan. 25	MT
Citigroup Raises Abbott Laboratories Price Target to $126 From $123, Maintains Buy Rating	Jan. 25	MT
Bernstein Raises Abbott Laboratories Price Target to $133 From $125, Maintains Outperform Rating	Jan. 25	MT
JPMorgan Raises Abbott Laboratories Price Target to $125 From $122, Maintains Overweight Rating	Jan. 25	MT
UBS Raises Abbott Laboratories Price Target to $136 From $122, Maintains Buy Rating	Jan. 22	MT
Wall St Week Ahead-Maligned US real estate sector draws buyers eyeing rate cuts	Jan. 21	RE
Wall St Week Ahead-Maligned US real estate sector draws buyers eyeing rate cuts	Jan. 19	RE
RBC Adjusts Abbott Laboratories' Price Target to $128 From $119, Keeps Outperform Rating	Jan. 11	MT
Raymond James Raises Abbott Laboratories' Price Target to $124 From $110, Maintains Outperform Rating	Jan. 03	MT
Wells Fargo Raises Price Target on Abbott Laboratories to $121 From $116, Maintains Overweight Rating	Dec. 13	MT
UBS Raises Abbott Laboratories Price Target to $122 From $118, Maintains Buy Rating	23-10-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Abbott Laboratories

Equities

ABT

US0028241000

Analyst Reco.

Filters